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Abstract
Chronic lymphocytic leukemia (CLL) is a heterogeneous disease without a well-defined genetic alteration responsible for the
onset of the disease. Several lines of evidence coincide in identifying stimulatory and growth signals delivered by B-cell
receptor (BCR), and co-receptors together with NFkB pathway, as being the driving force in B-cell survival in CLL. However,
the molecular mechanism responsible for this activation has not been identified. Based on the hypothesis that BCR
activation may depend on somatic mutations of the BCR and related pathways we have performed a complete mutational
screening of 301 selected genes associated with BCR signaling and related pathways using massive parallel sequencing
technology in 10 CLL cases. Four mutated genes in coding regions (KRAS, SMARCA2, NFKBIE and PRKD3) have been
confirmed by capillary sequencing. In conclusion, this study identifies new genes mutated in CLL, all of them in cases with
progressive disease, and demonstrates that next-generation sequencing technologies applied to selected genes or
pathways of interest are powerful tools for identifying novel mutational changes.
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Introduction
Chronic lymphocytic leukemia/small lymphocytic lymphoma
(CLL/SLL) is the most common adult leukemia in the western
world. Most CLL cells are inert and arrested in G0/G1 of the cell
cycle. However, it is the progressive accumulation of tumor cells
that ultimately leads to symptomatic disease. Pathogenic mecha-
nisms involve multiple external events (for instance, microenvi-
ronmental and antigenic stimuli) and internal events (genetic and
epigenetic) [1] that are associated with the transformation,
progression and evolution of CLL.
CLL is a heterogeneous disease. Some patients progress rapidly
and have short survival, whereas others have a more stable clinical
course that may not need treatment for years.
Previous studies have demonstrated that overexpression of genes
belonging to the B-cell receptor (BCR) pathway, and regulators,
such as CD79B, BTK, TNFRSF7 (CD27), IKB2 and SYK, are
correlated with a more aggressive behavior in CLL [2,3,4,5].
Along with this finding, oncogenic mutations in multiple genes
such as CARD11 [6], LYN [7] and A20 [8], among others, are
described as causing deregulation in the BCR and related
pathways, such as NFkB in B-cell lymphoma.
Several lines of evidence coincide in revealing that stimulatory
and growth signals delivered by BCR and co-receptors enable
lymphoma cells to avoid apoptosis and so to proliferate, thereby
constituting the driving force for B-cell survival. These seem to be
common features of lymphoma pathogenesis. It has been proved
that maintained signaling mediated via this pathway is an essential
mechanism for tumor cell survival in some lymphoma types, such
as CLL and diffuse large B-cell lymphoma (DLBCL) [9,10,11].
However, the molecular mechanism responsible for the activation
has not been fully clarified. On the basis of the hypothesis that
BCR activation may depend on somatic mutations of the BCR
genes and related pathways [12], we have used deep sequencing
technology to investigate the existence of changes in the coding
and regulatory sequences of a selection of 301 genes that are
associated with BCR, or related to signaling from the B-cell
receptor, such as the NFKB and JAK/STAT pathways.
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"Results
Clinical data of the 10 patients included in the study are shown
in Table 1. It is a heterogeneous group of patients in terms of
staging, genetic alterations and prognostic. Four of the patients
showed progressive diseases, which is defined as the need for
therapy, while stable disease is defined as those cases that do not
require therapy.
FISH analysis revealed a variety of cytogenetic abnormalities,
including del(13q), del(17p), del(11q) and trisomy 12. The most
frequent of these was del(13q), which was found in 6 of the 10
samples.
To explore whether BCR activation depends on somatic
mutations in BCR-signaling genes and related pathways, we used
single-end deep sequencing to perform a mutational screening of
the exonic and regulatory regions of 301 selected genes (Table S1).
The study pipeline and DNA sequencing data, including QC
metrics, are summarized in Figure S1 and Table S2.
In summary, detected variants were ranked by their VCF
QUAL parameter and manually reviewed in the IGV browser
(http://www.broadinstitute.org/igv/). The percentage of reads
supporting the mutation of the total number of reads at a given
position was taken as .20% with a minimum depth of 306 in
tumor DNA, and ,0.5% in normal DNA [13]. Selected
candidates (non-synonymous, nonsense or frameshift mutations,
or that affecting intronic or UTR regions) were validated by PCR
amplification of the genomic region and capillary sequencing (File
S1). Seven variants were selected for validation, and all of them
were validated by capillary sequencing (Table 2 and Figure 1).
Three of these mutations (present in KRAS, SMARCA2 and
PRKD3 genes) were non-synonymous point mutations, located in
the coding region of the genes. Two were G.A transitions and
one was an A.G change. There was also a frame-shift mutation
due to a 4-bp deletion (in NFKBIE gene) that resulted in a stop
codon 13 aminoacids downstream from it, which would generate a
truncated protein. The Ensembl Variant Effect Predictor (VEP)
[14] predicted that mutations in two of the genes (KRAS and
SMARCA2) were deleterious to protein function (Figure 2 and
Table 2).
The mutation in SMARCA2 lies inside the bromodomain of the
protein. Using the NMR structure of the bromodomain (PDB
code 2DAT, chain A) we were able to check that the WT residue is
placed in one of the loops of the bromodomain, opposite to the
region of the helical bundle involved in the binding with the acetyl-
lisine, and so the effect of this mutation is difficult to predict (data
not shown).
Finally, there were two point mutations located at intronic sites
(STAT6 and ILB1) and one in the 39 UTR (LIFR).
Mutations in coding sequences were detected in the 3 cases with
a progressive course. CLL7 and CLL5 (with 2 and 1 different
mutations, respectively) exhibited adverse prognosis factors, such
as unmutated IGVH (IGHV1-69 and IGHV2-70, respectively)
and ZAP-70 positivity; case CLL5 also harbor 17p13 deletion and
c-myc amplification. Case CLL9 progressed from stage RAI-
BINET A/0 at diagnosis to C/III. This case harbors del(13q) and
mutated IGVH3-21, a finding usually associated with a poor
prognosis, irrespective of the IGVH mutational status [15]
(Table 1).
Discussion
Based on the hypothesis that BCR activation may depend on
somatic mutations of the BCR and related pathways we have
performed a complete mutational screening of 301 selected genes
associated with BCR signaling and related pathways, such as
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Gene Mutations in CLL
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cases. Three out of four progressive cases included in the study
have mutated genes in the coding region. The mutated genes were
KRAS, SMARCA2, NFKBIE and PRKD3, all of which play a role in
BCR, NFkB and related signaling pathways.
The KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene
homolog) protein is a GDP/GTP-binding protein that acts as an
intracellular signal transducer, a molecular regulator in a variety of
signal transduction pathways, such as BCR signaling pathways
(Figure S2), or controlling phenomena such as cytoskeleton
integrity, proliferation differentiation, adhesion, cell migration
and apoptosis. From 17 to 25% of all human tumors have the
activating KRAS mutation, but it has been described in the
hematopoietic and lymphoid tissue of only about 5% of cases
(COSMIC database; http://www.sanger.ac.uk/genetics/CGP/
cosmic/). Specifically in CLL, KRAS mutations have been
described only exceptionally [16,17]. The mutation identified
here, located at codon 60, has not been described before, but is
located in the hotspot region of codons 59, 61 and 62. Therefore,
the putative effect of this mutation on protein function should be
similar, leading to the activation of the protein.
NFKBIE (nuclear factor of kappa light polypeptide gene
enhancer in B-cell inhibitor epsilon) is upregulated following NF-
kB activation. NFKBIE is able to inhibit NF-kB-directed
transactivation via cytoplasmic retention of REL proteins. For
NFKBIE, inactivating mutations have been described in Hodgkin/
Reed-Sternberg cells [18]. In the paper by Quesada et al.[19] a
non-sense mutation in a CLL case is also described (chr6:
44230329; C/A) and in the COSMIC database, two mutations are
described in breast cancer, one of which is a nonsense mutation,
like the one described here. This kind of mutation should give rise
to a truncated protein without the ankyrin motif mediating the
Figure 1. Mutation validation. Capillary sequencing chromatograms confirming the seven putative variants. KRAS, SMARCA2, PRKD3, STAT6, LIFR
and ILB1 showed one point mutation each, depicted as two peaks in the tumoral DNA chromatogram. For NFKBIE, the 4-bp deletion was also
confirmed. NT=non-tumoral, TM=tumoral. R=A or G; Y=C or T; S=C or G; K=T or G; /…./=4-bp deletion.
doi:10.1371/journal.pone.0038158.g001
Table 2. Validated somatic mutation.
Samples Position (hg19) Description Substitution Region SNV Type Prediction Gene Name
CLL2 chr5: 38478732 G-a NA 39UTR Non-coding NS LIFR
CLL5 chr6:44232738 -GTAA Frame-shift (253–254) Exon CDS Non-synonymous Truncated NFKBIE
CLL5 chr2:113590942 G-t NA Intronic Non-coding NS IL1B
CLL7 chr12:57493232 G-c NA Intronic Non-coding NS STAT6
CLL7 chr12:25380279 GGT-GaT G60D Exon CDS Non-synonymous Damaging KRAS
CLL7 chr9:2182166 CGG-CaG R1462Q Exon CDS Non-synonymous Damaging SMARCA2
CLL9 chr2:37505118 AAT-AgT N396S Exon CDS Non-synonymous Tolerated PRKD3
CDS: Coding sequence. NA: not annotated. Chr: chromosome.
doi:10.1371/journal.pone.0038158.t002
Gene Mutations in CLL
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The inactivation of NFKBIE by mutation would lead to the
sustained activation of the NFKB pathway (Figure S2), which has
previously been linked to CLL pathogenesis [20]
SMARCA2 (SWI/SNF related, matrix associated, actin depen-
dent regulator of chromatin, subfamily a, member 2), also known
as SNF2L2 or BRM, is part of the large ATP-dependent
chromatin remodeling complex SWI/SNF, which is required for
transcriptional activation of genes normally repressed by chroma-
tin. It has been described as a mediator of NFkB transcriptional
activation, and is also associated with BCR signaling mediated by
BTK [21,22]. (Figure S2). Four substitution mutations are
reported for the SMARCA2 gene in the COSMIC database and
in the ICGC portal (http://dcc.icgc.org/); two mutations were
identified and validated in CLL (intronic) and glioblastoma (non-
synonymous coding). The mutation found in the present study is
located in the bromodomain, whose function is not completely
clear although it may play a role in the assembly or activity of
multi-component complexes involved in transcriptional activation.
Mutations have been described in other members of the same
family, such as ARID1A in around 50% of ovarian clear cell
carcinomas and in gastric cancer [13,23,24], and SMARCA4/
BRG1 in lung tumors [25,26]. In both cases, mutations are located
throughout the entire gene coding sequence.
PRKD3 (protein kinase D3) belongs to the protein kinase C
family of serine- and threonine-specific protein kinases that can be
activated after BCR engagement [27] by calcium and the second
messenger, diacylglycerol (Figure S2). It phosphorylates a wide
variety of protein targets and is involved in diverse cellular
signaling pathways [28]. Only sporadic mutations have been
described in the PRKD3 gene in lung adenocarcinoma, ovary and
brain glioma (COSMIC and ICGC databases).
The other mutations found in STAT6, IL1B and LIFR, are
located in intronic regions and their consequences are therefore
not clear.
Recently, several groups have identified mutations in CLL using
exome sequencing [19,29,30], NOTCH1 being the most frequently
mutated gene that behaves as an independent predictor of poor
survival [30]. Other mutated genes identified in these studies were
SF3B1 [19,31], MYD88, KLHL6 and XPO1 [29], TP53, PLEKHG5,
TGM7 and BIRC3 [30].
Given the small number of patients included in the series, this
study is unable to conclude statistical significance. To infer a
possible role and relevance for each mutated gene described, they
need to be validated in a larger series of patients and through
functional studies. Nevertheless, the findings are consistent with
the idea that, at least partially, BCR and NFkB signaling and
related pathways in CLL cells could depend on somatic mutations.
In conclusion, this study identifies new genes mutated in CLL
and demonstrates that next-generation sequencing technologies
applied to selected genes or pathways of interest are powerful tools
for identifying novel mutational changes.
Materials and Methods
1. Clinical samples
The current study was approved by the institutional Ethics
Committee of the ‘‘Instituto de Salud Carlos III’’ (CEI PI
03_2011). Fresh blood samples from 10 untreated CLL patients
were obtained from Hospital Universitario Puerta de Hierro-
Majadahonda, with the collaboration of the CNIO Tumour Bank,
in adherence with the protocols of the Ethics Committee of the
Instituto de Salud Carlos III. All patients involved gave written
informed consent for their participation in the study. Clinical data
were collected according to the criteria of the National Cancer
Institute (NCI) Working Group [32].
Tumoral DNA was collected from peripheral blood cells,
CD19+ B-cell, then purified using the RossetteSep Human B cell
enrichment kit (StemCell Technologies) or an immunomagnetic
purification process (Myltenyi Biotec). Tumor cell purity was taken
to be the ratio CD19/CD3, which was measured by FACS. The
tumor B-cell purity of CLL samples after purification ranged from
88.00 to 99.80%. Non-tumoral DNA from each patient was
collected from oral mucosa samples.
DNA was extracted by the phenol–chloroform method and the
quality and quantity of purified DNA was assessed by fluorometry
(Qubit, Invitrogen) and gel electrophoresis.
Figure 2. Schematic representation of the mutated proteins with the primary structural domains highlighted. The locations of the
different somatic alterations found to be encoded in CLL samples are shown.
doi:10.1371/journal.pone.0038158.g002
Gene Mutations in CLL
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Gene selection and bait design. To select genes we
browsed the KEGG and BioCarta databases and previously
published data on CLL and genes acting on BCR signaling and
related pathways, such as NFkB and JAK/STAT [2,3,11,12,20]
(Table S1).
The USCS Genome Browser (http://genome.ucsc.edu/) was
used to select exonic sequences. A region 200 bp downstream of
the start transcription point was also included. The coordinates of
the genomic sequences were based on UCSC hg19.
The web-based design tool eArray (Agilent Technologies Inc,
Santa Clara, CA, USA) was used to design the baits for the
SureSelect Target Enrichment System kit.
Biotinylated-RNA 120-mer capture probes had sequences
complementary to those of the selected regions, and extended
20 bp upstream and downstream of each region. Repeat masked
regions were avoided in the design. The targeted region was
1.36 Mbp (up to 0.04% of the human genome), thereby consisting
of 4,000 exons and 580 ds regions. 35,985 capture-centered probes
were designed, allowing an overlap of 60 bp and a 46 tiling
frequency. The average tiling frequency achieved was 3.26,
because exons shorter than 120 bp had a unique complementary
probe.
Selected sequences were enriched for each library using the
SureSelect custom design Kit (Agilent Technologies).
Library preparation and sequencing. The protocol for
‘‘SureSelect Target Enrichment System’’ kit (Agilent Technolo-
gies) combined with the ‘‘Genomic DNA Sample Prep for single-
end sequencing’’ guide (Illumina, San Diego, CA, USA) were used
for sample sequence enrichment (31) and library preparation.
Briefly, 1–3 mg of high molecular weight genomic DNA from each
sample was fragmented by acoustic shearing on a Covaris S2
instrument. Fractions of 150–300 bp were ligated to Illumina’s
adapters and PCR-amplified for 6 cycles. Exon Enrichment:
300 ng of whole library were hybridized to SureSelect Oligo
Capture kit for 24 h at 65uC. Biotinylated hybrids were captured,
and the enriched libraries were completed with 12 cycles of PCR.
The resulting purified DNA library was applied to an Illumina
flow cell for cluster generation and sequenced using the Illumina
Genome Analyzer IIx for 36 bases in a single-read format by
following the manufacturer’s protocols.
3. Data analysis
Alignment, mapping and identification of somatic
variants. Sequencing data were first checked by FastQC
(http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc/) for
quality control checks on raw sequence data and then aligned to
the human reference genome (GRCh37) using Burrows-Wheeler
alignment (BWA). That reads unmapped by BWA [33] were
realigned using BFAST [34]. Somatic variants were identified
using the Unified Genotyper v2 available at the GATK [35]. For
variant calling we used GATK Unified Genotyper v2 applying the
‘‘Discovery’’ genotyping mode and default parameters for filtering.
Thus, SNPs available at dbSNP 132 (hg19) and those reported by
the 1000 Genomes Project were filtered out from VCF output files.
The GATK QUAL field was employed for ranking selected
somatic variants. The percentage of reads supporting the mutation
of the total number of reads at a given position was taken as .20%
in the tumor DNA, and ,0.5% in normal DNA [13]. Only those
variants showing a depth 306 in tumoral samples, were
considered for validation. Data has been deposited in the
Sequence Read Archive (SRA) database (http://www.ncbi.nlm.
nih.gov/sra) (SRA049097).
Biological impact predictions for detected variants were
obtained from Ensembl Variant Effect Predictor (VEP: http://
www.ensembl.org/tools.html) [14].
Supporting Information
Figure S1 Workflow. The USCS Genome Browser (http://
genome.ucsc.edu/) was used to select exonic sequences and the
web-based design tool eArray (Agilent Technologies) was used to
design the baits for the SureSelect Target Enrichment System kit.
The library was prepared and sequenced in a GA2 sequencer from
Illumina. Sequencing data were aligned to the human reference
genome (GRCh37) using Burrows-Wheeler alignment (BWA) and
BFAST. Somatic variants were identified using the Unified
Genotyper v2 available at the GATK. Somatic variants were
filtered by i) known SNPs available at dbSNP 132 (hg19) and those
reported by 1000 Genome Project, ii) changes present in the
matched germinal DNA and iii) synonymous changes. Ensemble
VEP was used to predict biological effect and, finally the variants
were ranked by GATK quality score, manually reviewed and
validated by capillary sequencing.
(PPT)
Figure S2 Mutations in components of B-cell receptor
signaling pathways. A modified KEGG (http://www.genome.
jp/kegg/) pathway including B-cell receptor signaling is depicted.
Somatically mutated genes in CLL are highlighted in red.
(PPT)
File S1 Supplementary Materials and Methods: Valida-
tion and sequencing.
(DOC)
Table S1 List of sequenced genes. 301 genes, belonging to
the BCR, NFkB and JAK/STAT signaling pathways, were
selected for sequencing.
(XLS)
Table S2 Quality control. Quality metrics of alignment,
mapping and coverage depth from the two independent
experiments. Mbp: Megabase pair. T: Tumoral. NT: Non-
tumoral.
(XLS)
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